TTrialPathMatch Me to Trials
← Back to trials
RecruitingRecurrent Acute Pancreatitis

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.

Eligible age

18–85 yrs

Accepts

All genders

Locations

3 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.

Sponsor: University of Alabama at Birmingham

Where it's recruiting

Alabama

Birmingham

Iowa

Iowa City

Minnesota

Rochester

Source: ClinicalTrials.gov · NCT06253117 · last updated 2026-07-29

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recu · TrialPath